A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study

被引:35
|
作者
Scott, Russell [1 ]
Morgan, Jerry [2 ]
Zimmer, Zachary [2 ]
Lam, Raymond L. H. [2 ]
O'Neill, Edward A. [2 ]
Kaufman, Keith D. [2 ]
Engel, Samuel S. [2 ]
Raji, Annaswamy [2 ]
机构
[1] Christchurch Sch Med, Lipid & Diabet Res Grp, Christchurch, New Zealand
[2] Merck & Co Inc, Kenilworth, NJ USA
来源
DIABETES OBESITY & METABOLISM | 2018年 / 20卷 / 12期
关键词
clinical trial; dapagliflozin; sitagliptin; type; 2; diabetes; POOLED ANALYSIS; KIDNEY-DISEASE; INHIBITORS; EQUATION;
D O I
10.1111/dom.13473
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim Materials and Methods To compare the efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin with the sodium-glucose transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes and mild renal insufficiency. Patients with HbA1c >= 7.0 to <= 9.5% (>= 53 to <= 80 mmol/mol) and estimated glomerular filtration rate >= 60 to <90 mL/min/1.73m(2) on metformin (>= 1500 mg/d) +/- sulfonylurea were randomized to sitagliptin 100 mg (n = 307) or dapagliflozin 5 mg titrated to 10 mg (n = 306) once daily for 24 weeks. A longitudinal data analysis model was used to test the primary hypothesis that sitagliptin is non-inferior to dapagliflozin in reducing HbA1c at Week 24, with superiority to be tested if non-inferiority is met. NCT02532855. Results Conclusions Baseline mean HbA1c (% [mmol/mol]) was 7.7 (60.9) and 7.8 (61.2), and mean eGFR (mL/min/1.73m(2)) was 79.4 and 76.9 for the sitagliptin and dapagliflozin groups, respectively. After 24 weeks, the between-group difference in least squares mean (95% CI) changes from baseline in HbA1c was -0.15% (-0.26, -0.04) (-1.67 mmol/mol [-2.86, -0.48]), P = 0.006, meeting the prespecified criteria for declaring both non-inferiority and superiority of sitagliptin versus dapagliflozin. The HbA1c goal of <7% (<53 mmol/mol) was met by 43% (sitagliptin) and 27% (dapagliflozin) of patients. No meaningful between-group difference was observed in a pre-specified analysis of 2-hour incremental postprandial glucose excursion. A review of adverse events (AEs) was notable for a lower incidence of drug-related AEs with sitagliptin compared with dapagliflozin. In patients with type 2 diabetes, mild renal insufficiency and inadequate glycaemic control on metformin +/- sulfonylurea, sitagliptin treatment resulted in greater improvement in glycaemic control compared with dapagliflozin and was generally well tolerated.
引用
收藏
页码:2876 / 2884
页数:9
相关论文
共 50 条
  • [21] Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
    Scheen, Andre J.
    Charpentier, Guillaume
    Ostgren, Carl Johan
    Hellqvist, Asa
    Gause-Nilsson, Ingrid
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2010, 26 (07) : 540 - 549
  • [22] Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency
    Ferreira, Juan Camilo Arjona
    Marre, Michel
    Barzilai, Nir
    Guo, Hua
    Golm, Gregory T.
    Sisk, Christine McCrary
    Kaufman, Keith D.
    Goldstein, Barry J.
    DIABETES CARE, 2013, 36 (05) : 1067 - 1073
  • [23] Efficacy and Safety of Dapagliflozin for Type 2 Diabetes Mellitus Patients With a History of Cardiovascular Disease
    Leiter, Lawrence A.
    Cefalu, William T.
    Debruin, Tjerk W.
    Gausenilsson, Ingrid
    Sugg, Jennifer
    Parikh, Shamik J.
    DIABETES, 2012, 61 : A287 - A287
  • [24] Efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus and concomitant heart failure
    Kosiborod, M.
    Gause-Nilsson, I.
    Sonesson, C.
    Johnsson, E.
    DIABETOLOGIA, 2015, 58 : S368 - S368
  • [25] Comparison of safety and efficacy of dapagliflozin and empagliflozin in type 2 diabetes mellitus patients in India
    Varshney, Amit
    Rawat, Ramakant
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2023, 69 (08):
  • [26] Clinical study of repaglinide efficacy and safety in type 2 diabetes mellitus patients with blood glucose levels inadequately controlled by sitagliptin
    Kawamori, Ryuzo
    Kaku, Kohei
    Hanafusa, Toshiaki
    Ioriya, Katsuhisa
    Kageyama, Shigeru
    Hotta, Nigishi
    JOURNAL OF DIABETES INVESTIGATION, 2016, 7 (02) : 253 - 259
  • [27] Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin
    Ba, Jianming
    Han, Ping
    Yuan, Guoyue
    Mo, Zhaohui
    Pan, Changyu
    Wu, Fan
    Xu, Lei
    Hanson, Mary E.
    Engel, Samuel S.
    Shankar, R. Ravi
    JOURNAL OF DIABETES, 2017, 9 (07) : 667 - 676
  • [28] Efficacy and safety of Sancai powder in patients with type 2 diabetes mellitus: a randomized controlled trial
    Guo Qiang
    Zhang Hengyao
    Li Mindian
    Zhao Ziyi
    Luo Yunlin
    Luo Yulei
    Cao Wenzhai
    Zhao Huan
    Zhu Ranran
    Lei Xingxing
    Chen Huizhen
    Gan Huakui
    Zuo Zhihuang
    Chen Qi
    Shi Cuimei
    Zhang Xinli
    Guo Jian
    Zhong Sen
    Chen Qiu
    Journal of Traditional Chinese Medicine, 2016, 36 (05) : 640 - 648
  • [29] Efficacy and safety of Sancai powder in patients with type 2 diabetes mellitus: a randomized controlled trial
    Guo Qiang
    Zhang Hengyao
    Li Mindian
    Zhao Ziyi
    Luo Yunlin
    Luo Yulei
    Cao Wenzhai
    Zhao Huan
    Zhu Ranran
    Lei Xingxing
    Chen Huizhen
    Gan Huakui
    Zuo Zhihuang
    Chen Qi
    Shi Cuimei
    Zhang Xinli
    Guo Jian
    Zhong Sen
    Chen Qiu
    JOURNAL OF TRADITIONAL CHINESE MEDICINE, 2016, 36 (05) : 640 - 648
  • [30] Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial
    Yang, Wenying
    Han, Ping
    Min, Kyung-Wan
    Wang, Bei
    Mansfield, Traci
    T'Joen, Caroline
    Iqbal, Nayyar
    Johnsson, Eva
    Ptaszynska, Agata
    JOURNAL OF DIABETES, 2016, 8 (06) : 796 - 808